I'm an Optometrist. Here's Why I Took My Own Mother Off Her Old Eye Vitamin.
A message from Klaris. This article is produced by Klaris and recommends Klaris Visual Performance Complex. It was medically reviewed for accuracy by Dr. Elena Markovic, MD.


My mother is 68. She has been taking the same eye vitamin since 2011.
For fifteen years, I recommended it to her. I recommended it to thousands of patients. It was the default. The one every pharmacist pointed to. The one printed on the take-home sheet at every optometry office in the country.
Last spring, I took it off her counter.
I replaced it with something most of my patients have never heard of. Not because the old formula was dangerous. Not because she had a bad reaction. But because, quietly, the science moved past it, and the shelf didn't.
If you, or someone you take care of, has been taking an AREDS2-based eye vitamin for a year or more, this is the conversation I wish I had with every one of my patients at their next visit.

1.Why I recommended that same formula for fifteen years
Most of the patients I see are over 55. Many come in with an inherited risk of macular degeneration, or with early signs of their own. The standard recommendation for this group has been the AREDS2 formula, published in 2013 by the U.S. National Eye Institute. It was a real study. It was well-designed. And it showed, for the first time, that a specific combination of nutrients could slow the progression of age-related macular degeneration.
The original formula was simple: Vitamin C, Vitamin E, Lutein, Zeaxanthin, Zinc, and Copper. That is almost exactly what every eye vitamin on the pharmacy shelf still contains today.
2013 was a long time ago. The research has not stood still.

2.What changed after 2013
1. The third carotenoid
The back of your eye has a small yellow patch called the macula. It is about the size of a dime. It is the only part of your eye capable of sharp, detailed vision. It is what lets you read a menu, recognize a face across a room, or see the difference between a 3 and an 8 on a car dashboard.

That yellow color comes from three plant pigments: lutein, zeaxanthin, and meso-zeaxanthin. Together they form your eye's internal blue-light filter.
The AREDS2 formula includes the first two. It does not include meso-zeaxanthin, because it was not a standard supplement ingredient when that trial was designed. But meso-zeaxanthin is the dominant pigment at the very center of your macula, the small spot called the fovea. The fovea is responsible for your sharpest vision. It is also the part of the retina that degenerates first.
If your current eye vitamin does not list meso-zeaxanthin, it is missing the pigment most concentrated in the part of your retina most at risk.
2. The focus muscle
Look at this page. Now look across the room. Now look back at this page. Every time you changed distance, a small ring of muscle inside your eye, called the ciliary muscle, squeezed and relaxed to reshape your lens.
After eight hours at a screen, that muscle goes into a kind of partial cramp. Your eyes feel heavy. Your vision blurs when you look up from your book. AREDS2 does nothing for this muscle. It was not designed to.

Astaxanthin, a deep-red pigment from a microalga, concentrates directly in the ciliary muscle. Multiple clinical trials have shown that astaxanthin reduces eye strain, improves focus endurance, and shortens the time it takes your eyes to recover after sustained near work. Most eye vitamins on the shelf include none.
3. The optic nerve's blood supply
The optic nerve is the cable that carries vision from your eye to your brain. It runs on a network of very small blood vessels.
A large analysis from the Women's Antioxidant and Folic Acid Cardiovascular Study followed women for seven years. The group taking a combination of folic acid, vitamin B6, and vitamin B12 had a lower incidence of age-related macular degeneration than the placebo group. (That trial used higher B-vitamin doses than most supplements contain.)
Most eye vitamins contain no B-vitamins at all. The ones that do often include them in inactive forms, which matters because about a third of adults have a common genetic variant (MTHFR) that makes converting inactive folate into its active form much less efficient.

3.The three things missing from almost every AREDS2 bottle
Put those three findings side by side, and you get a clear list:
- Meso-zeaxanthin, the pigment at the center of the retina.
- Astaxanthin, for the ciliary focus muscle.
- Active-form B-vitamins, for the optic nerve's blood supply.
There are two other issues that are harder to see on a label. The first is zinc form: the original AREDS2 trial used zinc oxide, which is cheap and poorly absorbed. The second is beta-carotene: it was shown to increase lung cancer risk in current and former smokers, and AREDS2 removed it in 2013, yet some general-use eye vitamins still contain it.
I came across Klaris in 2025. I read the label first, the way I read every label. I wanted to see if the company had built the formula that the research since 2013 actually pointed to, or if it was another AREDS2 copy in a different bottle.
It was not a copy. Klaris is what I would build if I sat down and wrote the ideal modern eye-vitamin spec.

| Lutein | 10 mg (from marigold) |
| Zeaxanthin | 2 mg (from marigold) |
| Meso-zeaxanthin | 10 mg |
| Astaxanthin | 4 mg (from red algae) |
| Vitamin C | 250 mg |
| Vitamin E | 134 mg |
| Active Vitamin B6 | 2 mg |
| Methyl folate | 400 mcg DFE |
| Methylcobalamin (B12) | 250 mcg |
| Zinc citrate | 25 mg |
| Copper citrate | 2 mg |
Eleven ingredients. No beta-carotene. No synthetic fillers. Plant-based throughout. Produced in an FDA-registered, GMP-certified facility.
For my mother, this consolidated what she had been taking across three bottles, her old eye vitamin, a B-complex, and a separate antioxidant, into one daily habit.
4.What to expect: a realistic timeline

These are general patterns from studies and clinical experience; individual results vary, and a supplement is not a treatment.
I tell every patient the same thing when they start a new formula. This is not a pain reliever. You will not feel an effect on day one. Macular pigment rebuilds on a tissue timescale.
Days 1 to 7. Active-form B-vitamins begin absorbing immediately. Astaxanthin starts accumulating in ciliary muscle tissue.
Weeks 1 to 3. The most common early change is reduced screen fatigue. Patients report that the 3 PM burn softens.
Months 1 to 2. Macular pigment density begins to measurably rebuild.
Months 3 to 4. Patients report small but real improvements in contrast. Menus in dim restaurants get easier. Night driving feels less stressful.
Months 5 to 6. The full protective effect settles in. Macular pigment density is near its new baseline.
"I didn't realize my eyes were getting tired that early in the day until they stopped." That is the most common thing patients say to me after sixty to ninety days on Klaris Supplement.
5.The bottom line

I am not writing this because I have a grudge against the AREDS2 formula. It was a genuine breakthrough. I used it for fifteen years.
I am writing this because the research has kept moving, and most of what you can buy at the pharmacy has not. The right update is not complicated. It is three ingredients, one cleaner mineral form, and the removal of one old one. That is exactly what the Klaris Supplement is.
My mother has been on it for a year. If you want to make the same switch I made for her, this is the formula I recommend.

Rated 4.8 / 5 based on 1,247+ verified reviews
This article is for general educational purposes and is not medical advice. If you have a diagnosed eye condition or are on medications, please discuss any new supplement with your eye care professional. These statements have not been evaluated by the Food and Drug Administration. Klaris is not intended to diagnose, treat, cure, or prevent any disease.
References
- Age-Related Eye Disease Study 2 (AREDS2) Research Group. JAMA. 2013.
- Nolan JM, et al. Macular pigment and visual performance in subjects with age-related macular degeneration. Curr Eye Res. 2016.
- Hammond BR, et al. The effects of macular pigment on visual performance. Vision Res. 2014.
- Piermarocchi S, et al. Carotenoids in age-related maculopathy: the CARMIS study. Eur J Ophthalmol. 2012.
- Christen WG, et al. Folic acid, B6, and B12 in combination and age-related macular degeneration. Arch Intern Med. 2009.